Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma
- PMID: 23232275
- DOI: 10.2967/jnumed.112.109603
Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma
Abstract
The aim of this study was to assess the clinical value of O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET) PET in the initial diagnosis of cerebral lesions suggestive of glioma.
Methods: In a retrospective study, we analyzed the clinical, radiologic, and neuropathologic data of 174 patients (77 women and 97 men; mean age, 45 ± 15 y) who had been referred for neurosurgical assessment of unclear brain lesions and had undergone (18)F-FET PET. Initial histology (n = 168, confirmed after surgery or biopsy) and the clinical course and follow-up MR imaging in 2 patients revealed 66 high-grade gliomas (HGG), 77 low-grade gliomas (LGG), 2 lymphomas, and 25 nonneoplastic lesions (NNL). In a further 4 patients, initial histology was unspecific, but during the course of the disease all patients developed an HGG. The diagnostic value of maximum and mean tumor-to-brain ratios (TBR(max/)TBR(mean)) of (18)F-FET uptake was assessed using receiver-operating-characteristic (ROC) curve analyses to differentiate between neoplastic lesions and NNL, between HGG and LGG, and between high-grade tumor (HGG or lymphoma) and LGG or NNL.
Results: Neoplastic lesions showed significantly higher (18)F-FET uptake than NNL (TBR(max), 3.0 ± 1.3 vs. 1.8 ± 0.5; P < 0.001). ROC analysis yielded an optimal cutoff of 2.5 for TBR(max) to differentiate between neoplastic lesions and NNLs (sensitivity, 57%; specificity, 92%; accuracy, 62%; area under the curve [AUC], 0.76; 95% confidence interval [CI], 0.68-0.84). The positive predictive value (PPV) was 98%, and the negative predictive value (NPV) was 27%. ROC analysis for differentiation between HGG and LGG (TBR(max), 3.6 ± 1.4 vs. 2.4 ± 1.0; P < 0.001) yielded an optimal cutoff of 2.5 for TBR(max) (sensitivity, 80%; specificity, 65%; accuracy, 72%; AUC, 0.77; PPV, 66%; NPV, 79%; 95% CI, 0.68-0.84). Best differentiation between high-grade tumors (HGG or lymphoma) and both NNL and LGG was achieved with a TBR(max) cutoff of 2.5 (sensitivity, 79%; specificity, 72%; accuracy, 75%; AUC, 0.79; PPV, 65%; NPV, 84%; 95% CI, 0.71-0.86). The results for TBR(mean) were similar with a cutoff of 1.9.
Conclusion: (18)F-FET uptake ratios provide valuable additional information for the differentiation of cerebral lesions and the grading of gliomas. TBR(max) of (18)F-FET uptake beyond the threshold of 2.5 has a high PPV for detection of a neoplastic lesion and supports the necessity of an invasive procedure, for example, biopsy or surgical resection. Low (18)F-FET uptake (TBR(max) < 2.5) excludes a high-grade tumor with high probability.
Comment in
-
Being sensitive: to specify when amino acid tracers accumulate in a brain lesion.J Nucl Med. 2013 May;54(5):826. doi: 10.2967/jnumed.113.122325. Epub 2013 Mar 27. J Nucl Med. 2013. PMID: 23536222 No abstract available.
-
Replay: being sensitive: to specify when amino acid tracers accumulate in a brain lesion.J Nucl Med. 2013 May;54(5):826-7. doi: 10.2967/jnumed.113.122960. Epub 2013 Mar 27. J Nucl Med. 2013. PMID: 23757488 No abstract available.
-
Discriminating ability of (18)F-FET PET for several cerebral neoplastic lesions.J Nucl Med. 2014 Jan;55(1):176. doi: 10.2967/jnumed.113.128231. Epub 2013 Nov 6. J Nucl Med. 2014. PMID: 24198384 No abstract available.
-
Reply: discriminating ability of (18)F-FET PET for several cerebral neoplastic lesions.J Nucl Med. 2014 Jan;55(1):176. doi: 10.2967/jnumed.113.134007. Epub 2013 Nov 6. J Nucl Med. 2014. PMID: 24198386 No abstract available.
Similar articles
-
Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.J Nucl Med. 2012 Sep;53(9):1367-74. doi: 10.2967/jnumed.112.103325. Epub 2012 Aug 7. J Nucl Med. 2012. PMID: 22872742
-
The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.J Neurosurg. 2018 Apr 6;130(2):451-464. doi: 10.3171/2017.8.JNS171577. Epub 2018 Apr 6. J Neurosurg. 2018. PMID: 29624154
-
Diagnostic accuracy of 13N-ammonia PET, 11C-methionine PET and 18F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma.BMC Cancer. 2019 Apr 8;19(1):332. doi: 10.1186/s12885-019-5560-1. BMC Cancer. 2019. PMID: 30961564 Free PMC article.
-
Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis.J Nucl Med. 2012 Feb;53(2):207-14. doi: 10.2967/jnumed.111.096859. J Nucl Med. 2012. PMID: 22302961
-
Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our Experience.Curr Radiopharm. 2019;12(3):220-228. doi: 10.2174/1874471012666190115124536. Curr Radiopharm. 2019. PMID: 30644351 Review.
Cited by
-
Current status of PET imaging in neuro-oncology.Neurooncol Adv. 2019 May 28;1(1):vdz010. doi: 10.1093/noajnl/vdz010. eCollection 2019 May-Dec. Neurooncol Adv. 2019. PMID: 32642650 Free PMC article. Review.
-
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.Neuro Oncol. 2016 Sep;18(9):1199-208. doi: 10.1093/neuonc/now058. Epub 2016 Apr 21. Neuro Oncol. 2016. PMID: 27106405 Free PMC article. Review.
-
Site-Specific Labeling of F-18 Proteins Using a Supplemented Cell-Free Protein Synthesis System and O-2-[18F]Fluoroethyl-L-Tyrosine: [18F]FET-HER2 Affibody Molecule.Mol Imaging Biol. 2019 Jun;21(3):529-537. doi: 10.1007/s11307-018-1266-z. Mol Imaging Biol. 2019. PMID: 30112727
-
FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):591-602. doi: 10.1007/s00259-018-4188-8. Epub 2018 Oct 16. Eur J Nucl Med Mol Imaging. 2019. PMID: 30327856
-
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):3970-3981. doi: 10.1007/s00259-023-06371-5. Epub 2023 Aug 11. Eur J Nucl Med Mol Imaging. 2023. PMID: 37563351 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical